Research Briefings Cancer, Depression, and St. John's Wort
The evidence for a role for psychological states in cancer survival continues to mount. A study by Loberiza et al 1 in the Journal of Clinical Oncology found decreased survival 1 year after hematopoetic stem cell transplantation for malignancy among patients assessed as having depressive syndrome (85% for depressed vs 94% for nondepressed patients; P = .04). After multivariate analysis to control for possible confounding factors, the relationship persisted. Decreased quality of life was also found among depressed survivors. The authors raise the possibility that treatment for depression may increase survival in stem cell transplantation patients. The wide availability of St. John's wort (Hypericum perforatum L., Hypericaceae), an herbal antidepressant, and the relevance of depression for survival in cancer raise the possibility that patients may self-treat for depression with this herbal supplement; the herb may be of interest to physicians in depression treatment as well, under certain circumstances. It is therefore of relevance to psycho-oncology to examine recent publications of clinical studies of St. John's wort.
Two recent studies have reported lack of effect of St. John's wort on major depression. 2, 3 The second of these is notable for including a positive control, the selective serotonin re-uptake inhibitor sertraline, in addition to the placebo control group. This trial, published by the Hypericum Depression Trial Study Group with funding from the National Center for Complementary and Alternative Medicine, used the well-characterized extract LI-160 (Lichtwer Pharma, Berlin), which has shown efficacy in many previous randomized trials, although usually in milder cases of depression.
The trial inclusion criteria were based on a score on the Hamilton rating scale for depression (HAM-D) of at least 20, a level indicating moderate depression. Major outcome measures were change in total HAM-D score from baseline to 8 weeks and rate of full response as determined by the HAM-D and the Clinical Global Impressions (CGI) scale. Sample size was computed based on an expectation of a 20% difference in effectiveness between either hypericum or sertraline (verum groups) and the placebo group. The power calculation indicated that a study of 336 patients would have an 85% chance of detecting a difference this large; 340 patients were thus randomized into the 3 groups. There were no differences in mean severity of depression or patterns of dropout rates in the 3 groups. The trial was conducted for 8 weeks, with an optional continuation period.
The results of the trial indicated no difference between the placebo group and either hypericum or sertraline. The mean change in HAM-D by week 8 was -9.20 for placebo (the more negative the score, the greater the improvement in condition), -8.68 for hypericum, and -10.53 for sertraline; the scores of the verum groups did not differ significantly from that of the placebo group. The rates of full response were 31.9% for placebo, 23% for hypericum, and 24.8% for sertraline, again with no significant difference between placebo and verum groups. Diarrhea, nausea, and sweating were side effects in the sertraline group; anorgasmia was a side effect in the sertraline and hypericum groups; and frequent urination and swelling were side effects in the hypericum group. A post hoc analysis indicated that on the improvement scale of the CGI, the sertraline group performed better than the placebo group, which was taken by the authors as an indication of superior performance of the conventional drug entity.
The latter result has been discussed in the press as an indication that hypericum is ineffective whereas sertraline is effective. However, this was a post hoc analysis of a secondary evaluation, and it must be acknowledged that neither sertraline nor hypericum differed from placebo on the main measures this trial was designed to assess.
An editorial by Kupfer and Frank 4 discusses the complexity of use of placebos in depression trials. Their assessment of the hypericum study is that, despite its large sample size and rigorous conduct, the trial was underpowered to detect the actual difference it encountered between drug and placebo: the power calculation was based on an ability to detect a 20% advantage for the verum groups versus the placebo group, when in actuality the placebo full response rate was higher than that of either verum group. They also point out that rather low doses of sertraline were used (although high doses of hypericum were allowed); had larger sertraline doses been permitted, the study might have shown a significant effect for this established antidepressive drug.
Other difficulties with the trial include the fact that the herbal extract used is one that is standardized on the putatively active compound hypericin, whereas there is evidence that another compound, hyperforin, may be a more potent antidepressive constituent of hypericum. 2 In addition, it is questionable whether the efficacy and proper dosage of hypericum in moderate to severe major depressive disorder were adequately established in previous trials, although there is some evidence for its efficacy in moderate depression. For instance, a study by Vorbach et al 5 used a dosage of 1800 mg extract for moderately depressed patients and indicated efficacy, whereas the maximum dosage permitted for the new hypericum trial was only 1500 mg and the mean highest dosage used was only 1300 mg. Patients in this trial may thus not have received adequate dosages of hypericum extract.
Interesting data on the placebo response in depression were recently published by Khan et al, 6 who analyzed 45 trials in the database of the Food and Drug Administration. This study found that the size of reduction in HAM-D scores was significantly related to the initial HAM-D scores. In studies with higher mean scores on HAM-D, antidepressant-treated groups had a larger response whereas placebo-treated groups had a lower response.
This study raises questions about our ability to conduct large, well-designed trials on the effect of hypericum on mild to moderate depression, for which it is usually prescribed. From the findings of Khan et al, one would expect that studies of mild depression, with lower mean HAM-D scores, would result in lower response rates in verum groups. Placebo groups, on the other hand, might be predicted to have a better response, with lower HAM-D scores. This inverse relationship of severity of depression and placebo response might mean that studies of mild to moderate depression would be difficult to design and might require very large populations. As noted below ("Nature of the Placebo Effect"), there is evidence that the placebo response in depression studies has been increasing in recent years, which would add to these difficulties.
Nature of the Placebo Effect
Walsh et al 1 present a meta-analysis of 75 trials of major depressive disorder in which they show that the proportion of patients responding to placebo has risen during the past 20 years. They found that the age of patients in trials and the use of placebo lead-in periods were not correlated with the degree of placebo response. However, the length of trial, the minimum HAM-D score for inclusion (prorated according to the number of items on the scale used, which differed among versions), and the year of publication were correlated with placebo response. Multiple linear regression eliminated the trial length and the minimum HAM-D score as statistically significant variables, leaving the year of publication as the only variable significantly predicting response rate. Specifically, the more recent the year of publication, the higher was the placebo response rate. In fact, both the placebo response (r = 0.45) and the active response (r = 0.27) were correlated with the year of publication, but further analysis of the correlations indicated that the correlation of year of publication with placebo response was more statistically robust than the correlation of year of publication with active response.
This study on the time-linked nature of the placebo response adds a new data set to an ongoing discussion and controversy about the nature and meaning of the placebo effect. Why would placebo response rise through time, in a manner not explained by variables such as severity of disease or length of trial? What is placebo effect?
A meta-analysis by Hrobjartsson and Gotzsche 2 asserts that the placebos have no significant clinical effect in actual trials. These investigators searched the literature for trials in which patients were randomly assigned to either placebo groups or groups that received no treatment at all; in all but 2 of the 114 trials used in the meta-analysis, an active treatment group was also included. Trials on 40 conditions (hypertension, menopause, infections, nausea, pain, and others) were included in an effort to separate placebo effects from such effects as regression to the mean and the fluctuating natural history of many diseases, both of which may induce improvements in placebo groups without adducing any special effect of taking placebo medications. The meta-analysis showed that placebo treatment was not different from no-treatment groups in studies that had either subjective or objective binary (yes or no) outcomes. In trials with variables that were measured in a continuous fashion, placebos had a beneficial effect compared to the no-treatment groups, but the effect was small and tended to disappear for studies with larger sample sizes. In trials on pain, there was a significant reduction of pain in placebo groups versus no-treatment groups, which amounted to 6.5 mm on a 100 mm visual analog pain scale. The study authors point out that they do not advocate ceasing randomized placebo-controlled trials, as placebo groups are critical to annul the effects of unconscious investigator bias; they nevertheless assert that the idea that placebos could be useful in clinical work has no support based on the data they examined. This study was interpreted by some journalists as destroying not only the validity of the concept of the placebo effect but also the credibility of mind-body medicine in general, summarily dismissing mind-body medicine as the notion that patients can "think themselves well." 3 Numerous responses to the study of Hrobjartsson and Gotzsche 2 have been made. Of special interest to readers of this journal may be those in the journal Advances in Mind-Body Medicine, where Hrobjartsson and Gotzsche responded to critiques submitted by authors working in the areas of psychoneuroimmunology, placebo response, and complementary medicine. [4] [5] [6] [7] [8] [9] Hrobjartsson and Gotzsche point out at the beginning of their response that it is a misinterpretation to assert that their study shows a lack of psychologically mediated effects on health, or implies a lack of importance to the doctor-patient relationships. The authors of critiques raise a large number of issues, many of which Hrobjartsson and Gotzsche point out are not directly related to the topic of their article. Some of the issues raised include the notable variability in the types of studies included in the analysis, which some statisticians feel is incompatible with the assumptions of meta-analysis; the variability of types of placebos used (eg, psychological, physical, pharmacological), which is problematic due to the different effects of placebos of different types; the loss of information in binary outcomes relative to continuous outcomes, which may lead to the lack of placebo effects on binary variables; and questions about the means of selecting studies for the meta-analyses. There is also a lack of examination of different disease conditions (only pain was able to be examined specifically), of the extent to which patients in the meta-analysis studies had guessed that they were in placebo groups, and a lack of any coherent definition of placebo effect itself (Hrobjartsson and Gotzsche refrained from such a definition and simply accepted as placebos whatever intervention was designated as placebo in the studies analyzed). There was little exploration of the "nocebo" effects of placebo treatments, the ability of placebo interventions to produce adverse side effects.
In addition to raising methodological points, the critiques cited many studies not included in the metaanalysis that indicate the validity of the concept of placebo or placebo-like effects. Although these studies may not have met the inclusion criteria for the metaanalysis, they are, nevertheless, interesting studies that bear on the question of how the treatment relationship may affect the health of patients. Studies cited by, for instance, Greene et al 6 report findings of greater relief among ulcer patients who take larger numbers of placebo pills (4 daily vs 2 daily). These authors also cite studies in which asthma patients given placebo medication responded differently depending on the instructions given with the medication, as well as several studies on the potential mechanisms of placebo analgesia, which appear to involve endogenous opioids.
Other recent work on the placebo effect includes an article by Papakostas and Daras 10 on the evolution of the placebo concept. These authors review the history of the concept of the placebo and its place in research. One of the notable points in this article is the analysis of the active control equivalence trial-the trial in which a new drug (or procedure) is tested against an old drug known to be effective. Such trials may be advocated in conditions for which well-known drugs exist (such as depression); they can be felt to be more ethical because patients will not be exposed to potential danger from lack of effective treatment. However, these authors point out that the greater risk is that ineffective drugs might be approved should these trials become customary; both treatments may, in fact, be ineffective when compared with the placebo group (as was seen in the recent hypericum trial), or the study may be underpowered. Papakostas and Daras point out, interestingly, that one third to one half of randomized controlled trials are found to show no effect of active drugs even when the agents are known to be clinically useful. They also note that the concept of the "placebo responder," the person more likely than most to respond to placebo, has not been validated in empirical studies.
Papakostas and Daras 10 accept the reality of the placebo effect and advocate its application to the healing situation, sketching out potential uses of "placebogenic" techniques in medicine; these techniques if used by medical personnel are claimed to be potentially useful in calling forth the healing tendencies that the placebo response taps. They include such things as offering prescriptions with optimism, as well as counseling about the time course of the disease and the types of side effects; attending to the perceptual qualities of medications (eg, people react to red placebo pills as if they were stimulants and blue ones as if they were sedatives); structuring more invasive treatment options, as these are associated with larger placebo effects; and making sure to explore "nocebogenic" effects (adverse side effects of placebos) of medications/procedures so that patients may be warned about them in order to help increase adherence. These are all felt to be useful elements of the doctor-patient relationship.
Moerman and Jonas 11 also examine the nature of the placebo concept and the need to differentiate it from factors such as regression to the mean, natural history of disease, and unconscious investigator bias. They propose a different term, which may apply to the types of studies mentioned above in which instructions or number of pills-the social context of placebo drug delivery-play a role in effect. This term, the "meaning response," refers to the "physiologic or psychological effects of meaning in the origins or treatment of illness." 11 Meaning responses elicited by the administration of sham treatments can be called placebo effects. Moerman and Jonas have thus usefully separated the dimensions of the social context of delivery of treatment from the statistical effects such as natural history of disease. In support of the importance of meaning responses, they explore the culturebound effects of meaning. In one example, the differences in death rates in Chinese Americans and whites are related to years considered lucky or unlucky by Chinese traditional astrology, as they relate to specific disease types. Chinese Americans who died of lymphatic cancers who were born in unlucky years died at an average age of 4 years younger than Chinese Americans who were not born in unlucky years; no such pattern was seen in whites. This 4-year difference represents nearly 7% of the entire life span and is apparently based largely on meaning.
Meaning, Moerman and Jonas 11 observe, has been taken out of medicine as it becomes progressively rationalized. They question whether we have lost something in the translation. Debate on placebo and meaning responses is currently ongoing, and our directions, beyond the recognition of the continuing validity of both randomized placebo-controlled trials and mind-body medicine, are still unclear. What are the meanings, for instance, of different placebos used in studies of complementary medicine, and do they affect our ability to study these techniques? Has the meaning of antidepressant treatment changed over the past 2 decades, giving rise to the trend of increasing placebo responses? Or do the time-linked differences in placebo response arise from changes in populations recruited for clinical studies during that time? As doctors and patients try to optimize integrative treatment, both technical and psychological questions about placebo responses need deeper examination.
